GlassScriptPhysician profile
Swathy Kolli
NPI 1942224878
$4,479.24
in general payments reported to CMS, 2019-2025
25 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.80 · 2021: $307 · 2022: $33.63 · 2023: $635 · 2024: $2,378 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $962.47 | 2023-2025 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $372.96 | 2022-2025 | Farxiga, Wainua |
| Amgen INC. | $348.59 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $341.88 | 2021-2025 | Nexletol |
| Abbott Laboratories | $329.08 | 2021-2024 | Cardiomems |
| Shockwave Medical, INC | $313.50 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $309.62 | 2023-2025 | |
| Medtronic, INC. | $200.97 | 2023-2024 | Venaseal, Hawkone |
| Boston Scientific Corporation | $191.61 | 2023-2025 | Watchman Access System, Bodyguardian |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.92 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $131.46 | 2024-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $129.00 | 2023-2024 | |
| Alnylam Pharmaceuticals INC. | $113.68 | 2024-2025 | Onpattro |
| Abiomed | $96.94 | 2024 | Impella |
| Novo Nordisk INC | $94.15 | 2024-2025 | Wegovy, Ozempic |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $93.81 | 2023-2024 | Xarelto |
| Cvrx, INC. | $58.68 | 2025 | Barostim Neo System |
| Atricure, INC. | $47.46 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Daiichi Sankyo INC. | $44.29 | 2024-2025 | Injectafer |
| Pfizer INC. | $28.03 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.08 | 2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $22.50 | 2023 | Livalo |
| Merck Sharp & Dohme LLC | $20.06 | 2024 | Verquvo |
| Heartflow, INC. | $19.74 | 2022 | |
| Philips North America LLC | $15.76 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swathy Kolli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.